With the explosion of GLP-1–based therapies for type 2 diabetes and weight loss, perioperative nursing teams, especially in the preoperative and postanesthesia care areas, need to be fluent in recognizing these medications. Some patients may arrive on these agents—or even novel oral GLP-1s—and the physiologic effects, especially delayed gastric emptying, can influence anesthesia risk, aspiration precautions, and timing decisions.
This article aims to help perioperative nurse managers and advanced practice leaders recognize GLP-1 agents by name, understand relevant considerations, and partner with anesthesia and endocrinology to mitigate risk.
GLP-1 (glucagon-like peptide-1) receptor agonists (GLP-1 RAs) are a class of medications that mimic the incretin hormone GLP-1. They enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety/weight loss. Many GLP-1 RAs are peptides or analogs and are delivered via subcutaneous injection; some newer ones are taken orally. In addition, dual or multi-agonist agents (eg, GLP-1 + GIP) are in use or development (eg, tirzepatide) and may share many of the same concerns.
A recently described oral small-molecule GLP-1 agonist, orforglipron, is being developed for weight loss/diabetes. Orforglipron is a once-daily pill under clinical investigation. Because it is investigational—meaning it is still in clinical trials and not approved by the US Food and Drug Administration—it would only appear on a medication list if the patient is part of a research study. In such a situation, perioperative nurses should alert the anesthesia and surgical teams immediately, since clinical trial medications often have specific protocols about whether they can be held, continued, or need special documentation in the perioperative setting.
Below is a non-exhaustive list of GLP-1 / GLP-1–based agents commonly seen in clinical practice or emerging, with their dosing cadence and key notes. (This is useful for OR/preop nurses to flag in medication histories.)
| Generic (trade name[s]) | Dosing interval / route | Notes / considerations |
| Exenatide (Byetta, Bydureon) | Twice daily (Byetta), once weekly (Bydureon) | One of the older GLP-1 agents |
| Lixisenatide (Adlyxin) | Daily | Short-acting GLP-1 |
| Liraglutide (Victoza for diabetes, Saxenda for obesity) | Daily | Moderate half-life; GI side effects common; often used in weight loss contexts |
| Dulaglutide (Trulicity) | Weekly | Long-acting; slow washout |
| Semaglutide (Ozempic [weekly injectable], Rybelsus [oral daily], Wegovy [for weight]) | Weekly (injectable) or daily (oral) | Among the most used agents currently; oral semaglutide (Rybelsus) deserves special attention |
| Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) | Weekly | Dual GLP-1/GIP action; similar gastric effects expected |
| Orforglipron (in development) | Oral daily (investigational) | A non-peptide oral GLP-1 agonist in clinical development |
Because these medications are relatively new in widespread use (especially for weight loss), many patients or even providers may not realize their significance in the surgical/anesthetic context. An OR nurse who sees “Rybelsus,” “Ozempic,” “Wegovy,” or “Trulicity” in the preop medication list should immediately consider whether the anesthetic team should adjust fasting or induction plans.
1. Delayed gastric emptying, aspiration risk
One of the fundamental physiologic effects of GLP-1 RAs is slowing gastric motility (gastric emptying). Even when patients have fasted appropriately per standard preoperative guidelines, multiple reports and small studies have documented residual gastric contents in patients using GLP-1 therapy.
Because pulmonary aspiration is one of the most feared complications under anesthesia, delayed gastric emptying is a nontrivial risk that anesthesiologists (and affiliated nursing teams) want to mitigate.
2. Fasting and “full stomach” planning
If a patient on a GLP-1 agent is not managed appropriately, the anesthesiologist may need to treat them as having a “full stomach” (eg, rapid sequence induction, modified techniques). Some guidance suggests using preoperative gastric ultrasound to stratify risk. Nurses in preop can flag these patients early so anesthesia and surgical teams can plan accordingly.
3. Balancing glycemic control vs discontinuation risk
Stopping a GLP-1 agent before surgery may worsen glycemic control, increase insulin requirements, or precipitate perioperative hyperglycemia. Avoiding abrupt discontinuation without plan (or “bridging”) may also create patient discomfort or rebound GI side effects. The decision whether to pause or continue a GLP-1 agent perioperatively must be individualized, often in consultation with endocrinology/medicine, and communicated early.
4. Emerging data on outcomes, delay windows, risk stratification
Recent literature is evolving rapidly. For example:
Because recommendations are shifting, perioperative nursing leadership should stay abreast of institutional protocols, evolving ASA or anesthesiology guidance, and endocrinology best practices.

1. Update preoperative questionnaires/medication checklists
2. Develop a “GLP-1 flag protocol”
3. Coordinate with anesthesia and endocrine/medicine teams
4. Fasting and intake modifications
5. Gastric ultrasound or point-of-care tools
6. Educate your team and reinforce awareness
7. Monitor outcomes and feedback loops
Despite the growing attention to GLP-1 receptor agonists in the perioperative setting, the available evidence remains limited. Much of what is known today comes from case reports, small observational series, and expert consensus rather than large randomized controlled trials. This means that many recommendations—including how long to withhold these medications prior to surgery—are based on clinical judgment and evolving best practices rather than definitive data.
A key challenge is balancing the benefits of continuing GLP-1 therapy, such as improved glycemic control and cardiometabolic outcomes, against the potential aspiration risk associated with delayed gastric emptying. Different guidelines vary in their recommendations, with some suggesting discontinuation a week or more in advance of elective procedures and others supporting continuation in many patients, especially those without significant gastrointestinal symptoms.
Adding to the complexity, new GLP-1 agents—particularly oral small-molecule drugs such as orforglipron—are advancing through clinical trials. These agents may have unique pharmacokinetics that further alter perioperative management strategies. As these drugs reach clinical practice, institutional protocols will need to adapt accordingly.
Ultimately, there is broad agreement that more robust evidence is needed. Large prospective studies and randomized trials will be essential to better quantify the actual risk of aspiration, to determine optimal discontinuation intervals, and to identify safe and effective perioperative management strategies. Until then, perioperative teams should remain vigilant, apply institutional protocols, and maintain close interdisciplinary communication when caring for patients on GLP-1 therapy.
As GLP-1 receptor agonist use (injectable and oral) continues to grow, perioperative teams cannot afford to ignore them. By making GLP-1 awareness part of standard preoperative workflow, perioperative leaders help protect patients from aspiration risk and support smoother anesthetic planning.
—Tarsilla Moura is content director of OR Manager.